New Hope Network is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

First Carbonated Beverage Line Certified 'Glycemic Index Tested'

HILLSIDE, N.J., May 1, 2007 (PrimeNewswire via COMTEX) -- Setting a new standard in the beverage industry, Integrated BioPharma, Inc.'s, integrated biopharma inc wholly owned subsidiary, The Organic Beverage Company, today announces the successful completion of human clinical trials establishing the very first carbonated beverage line to be certified as Glycemic Index Tested.

The Organic Beverage Company ("TOBC") has been a leader in addressing the functional beverage market with healthy, alternative beverages designed to provide consumers with choices when selecting a beverage. The TOBC's product Syzmo(tm), pronounced (s-is-mo), has been the world's first USDA certified organic energy drink and now establishes another trendsetting first as the first certified Glycemic Index Tested carbonated beverage line. Additional product attributes include great taste profiles, a full compliment of RDA vitamins, and most of all, no High Fructose Corn Syrup.

Glycemic Index Laboratories, Inc. of Toronto, Canada, completed human clinical trials to determine the Glycemic Index of Syzmo(tm). The clinical study yielded a GI rating of 30, which is categorized as a Low GI rating. Beverages that are sweetened with glucose, high fructose corn syrup, granulated sugars, or other natural sweeteners generally would not qualify as Low GI rated products. Under a license agreement with Glycemic Index Ltd, a not for profit company composed of the University of Sydney, Diabetes Australia and the Juvenile Diabetes Research Foundation of Australia, Syzmo(tm) will now prominently display the international seal for Glycemic Index Tested products and will also display the GI rating along with an explanation of the Glycemic Index rating; GI is a ranking of carbohydrates and their effect on blood glucose levels.

"This new certification gives consumers the ability to choose healthier beverages based upon GI ratings and provides additional credibility to our beverages in the market," says Jeffrey O'Neal, President, The Organic Beverage Company. "While we've been recognized as the leader in USDA organic energy drink category, we've now advanced that a step further being the very first carbonated beverage to be certified Glycemic Index Tested."

Alan Barclay, Acting CEO Glycemic Index Ltd. of Sydney Australia indicated, "We're pleased with the developments from The Organic Beverage Company in pioneering Glycemic Index Testing in the carbonated and functional beverage markets." Dr. Alexandra Jenkins, Vice President, Glycemic Index Laboratories, Inc. of Toronto, Canada who has been involved in research related to the Glycemic Index since its inception more than twenty years ago stated: "We are excited to see an increase in the awareness of the Glycemic Index in the marketplace and the efforts by industry, such as The Organic Beverage Company, to increase the availability of low GI products."

Syzmo(tm) is packaged in a unique SLEEK can from Rexam, and is currently sold at many natural and specialty grocery outlets nationwide. The Organic Beverage Company expects to expand into the mass grocery and convenience channels in 2007, making its healthy energy drink available to mainstream consumers. Additional information on The Organic Beverage Company and its product Syzmo(tm) can be obtained from our website, or by calling (866) 637-8802.

About Integrated BioPharma, Inc. (INBP)
Integrated BioPharma, Inc. is a unique grouping of companies presently serving the varied needs of the health care industry. Through its nutraceutical business, the Company creates, develops, manufactures and markets products worldwide. The Company's biotechnology business uses its patented plant-based technology to produce vaccines and therapeutic antibodies. Its pharmaceutical business operates a GMP facility for the production and sale of Paclitaxel and related drugs and provides technical services through its contract research organization. Further information is available at

Statements included in this release related to Integrated BioPharma, Inc. may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such Statements involve a number of risks and uncertainties such as competitive factors, technological development, market demand, and the company's ability to obtain new contracts and accurately estimate net revenues due to variability in size, scope and duration of projects, and internal issues in the sponsoring client. Further information on potential risk factors that could affect the company's financial results can be found in the company's Reports filed with the Securities and Exchange Commission.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.